GlassScriptPhysician profile
Richard Philip Silton
NPI 1225063431
$11,770.03
in general payments reported to CMS, 2019-2025
36 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,446 · 2020: $1,435 · 2021: $1,787 · 2022: $2,120 · 2023: $1,425 · 2024: $1,238 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,960 · Consulting Fee: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,960.07 |
| Consulting Fee | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,438.91 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,393.25 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,159.30 | 2019-2025 | Dupixent |
| Csl Behring | $869.04 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $666.61 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Pfizer INC. | $638.02 | 2019-2025 | |
| Genzyme Corporation | $588.66 | 2019-2024 | |
| Grifols USA, LLC | $507.74 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $464.82 | 2019-2025 | Ruconest |
| Alk-Abello, INC | $428.81 | 2019-2022 | |
| Kaleo, INC. | $329.18 | 2019-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $288.50 | 2019-2025 | |
| Octapharma USA, INC. | $229.11 | 2019-2022 | |
| Optinose US, INC. | $216.58 | 2019-2025 | |
| Leo Pharma INC. | $205.94 | 2022-2023 | Adbry |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $169.68 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $142.45 | 2021-2023 | Orladeyo |
| Abbvie INC. | $140.50 | 2022-2025 | |
| Amgen INC. | $113.08 | 2021-2024 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $83.43 | 2019-2022 | |
| Genentech USA, INC. | $81.06 | 2019-2024 | Xolair |
| Aytu Biopharma, INC. | $76.46 | 2020-2025 | Karbinal |
| Incyte Corporation | $71.34 | 2022-2024 | Opzelura |
| Phadia US INC. | $71.22 | 2020 | |
| Covis Pharma Gmbh | $59.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.58 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $40.61 | 2025 | Alvesco |
| Gc Biopharma USA, INC. | $40.51 | 2025 | Alyglo |
| Organon LLC | $36.27 | 2025 | Nexplanon |
| Tersera Therapeutics LLC | $35.80 | 2023 | Quzyttir |
| Mylan Specialty L.P. | $33.09 | 2021 | |
| Ionis Pharmaceuticals, INC. | $24.47 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $22.58 | 2024 | |
| Hikma Pharmaceuticals USA | $19.18 | 2024 | Ryaltris |
| Philips North America LLC | $18.61 | 2019 | |
| Circassia INC. | $15.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Silton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.